These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29247634)

  • 1. Comparison of Single Nucleotide Polymorphism genotyping of CYP2C19 by Loop-mediated isothermal amplification and real-time PCR melting curve analysis.
    Kwong KM; Tam CC; Chan R; Lee SWL; Ip P; Kwok J
    Clin Chim Acta; 2018 Mar; 478():45-50. PubMed ID: 29247634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Diagnostic Utility of the Point-of-Care CYP2C19 Genotyping Assay in Patients with Acute Coronary Syndrome Dosing Clopidogrel: Comparison with Platelet Function Test and SNP Genotyping.
    Choi JL; Kim BR; Woo KS; Kim KH; Kim JM; Kim MH; Han JY
    Ann Clin Lab Sci; 2016 Sep; 46(5):489-94. PubMed ID: 27650615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visualized detection of single-base difference in multiplexed loop-mediated isothermal amplification amplicons by invasive reaction coupled with oligonucleotide probe-modified gold nanoparticles.
    Lu Y; Ma X; Wang J; Sheng N; Dong T; Song Q; Rui J; Zou B; Zhou G
    Biosens Bioelectron; 2017 Apr; 90():388-393. PubMed ID: 27960145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effects of cytochrome P450 2C19 genetic polymorphism on clopidogrel resistance and recent prognosis of patients with acute coronary syndrome].
    Li SN; Liu Z; Luo Y; Chen PA; Lei XM; Li GL
    Zhonghua Nei Ke Za Zhi; 2013 Nov; 52(11):961-5. PubMed ID: 24439192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of a CYP2C19 genotyping assay for clinical use.
    Cervinski MA; Schwab MC; Lefferts JA; Lewis LD; Lebel KA; Tyropolis AM; Pflueger SM; Tsongalis GJ
    Am J Clin Pathol; 2013 Feb; 139(2):202-7. PubMed ID: 23355205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and application of a real-time loop-mediated isothermal amplification system for the detection of CYP2C19 polymorphisms.
    Zhang C; Yao Y; Zhu JL; Zhang SN; Zhang SS; Wei H; Hui WL; Cui YL
    Sci Rep; 2016 Jun; 6():26533. PubMed ID: 27246657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population.
    Guo YM; Zhao ZC; Zhang L; Li HZ; Li Z; Sun HL
    Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27323099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic and cytogenetic evaluation in CYP2C19*2 and CYP2C19*3 allelomorphism in South Indian population with clopidogrel therapy.
    Tantray JA; Reddy KP; Jamil K; Kumar YS
    Int J Cardiol; 2017 Feb; 229():113-118. PubMed ID: 27915083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel.
    Langaee T; El Rouby N; Stauffer L; Galloway C; Cavallari LH
    Genet Test Mol Biomarkers; 2019 Mar; 23(3):209-214. PubMed ID: 30758238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
    Jiang M; You JH
    Pharmacogenet Genomics; 2015 Dec; 25(12):609-17. PubMed ID: 26398625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and portable, lab-on-chip, point-of-care genotyping for evaluating clopidogrel metabolism.
    Marziliano N; Notarangelo MF; Cereda M; Caporale V; Coppini L; Demola MA; Guidorossi A; Crocamo A; Pigazzani F; Boffetti F; del Giudice F; Orsini F; Pirola D; Cocci A; Manzalini C; Casu G; Bianchessi M; Ardissino D; Merlini PA
    Clin Chim Acta; 2015 Dec; 451(Pt B):240-6. PubMed ID: 26453416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related CYP2C19 Genotyping in China: A Novel Approach.
    Lin G; Yi L; Zhang K; Wang L; Zhang R; Xie J; Li J
    PLoS One; 2015; 10(7):e0134174. PubMed ID: 26218263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between platelet-derived microRNAs and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in patients with ACS.
    Peng L; Liu J; Qin L; Liu J; Xi S; Lu C; Yin T
    Thromb Res; 2017 Sep; 157():97-102. PubMed ID: 28734158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
    Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia).
    Fedorinov DS; Mirzaev KB; Ivashchenko DV; Temirbulatov II; Sychev DA; Maksimova NR; Chertovskih JV; Popova NV; Tayurskaya KS; Rudykh ZA
    Drug Metab Pers Ther; 2018 Jun; 33(2):91-98. PubMed ID: 29738309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
    Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M
    Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of clopidogrel: comparison between a standard and a rapid genetic testing.
    Saracini C; Vestrini A; Galora S; Armillis A; Abbate R; Giusti B
    Genet Test Mol Biomarkers; 2012 Jun; 16(6):500-3. PubMed ID: 22239289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention.
    Tang XF; Zhang JH; Wang J; Han YL; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yang YJ; Yuan JQ
    Chin Med J (Engl); 2013 Mar; 126(6):1069-75. PubMed ID: 23506580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry.
    Mărginean A; Bănescu C; Moldovan V; Scridon A; Mărginean M; Bălaşa R; Maier S; Ţăruşi M; Dobreanu M
    Clin Appl Thromb Hemost; 2017 Apr; 23(3):255-265. PubMed ID: 26873108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.